XML 43 R29.htm IDEA: XBRL DOCUMENT v3.25.3
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2025
Accounting Policies [Abstract]  
Schedules of Concentration of Credit Risk
Customers that accounted for 10% or greater of accounts receivable, net as of September 30, 2025 and December 31, 2024 were as follows:
September 30,
2025
December 31,
2024
Customer A62%*
Customer B*36%
Customer C*17%
Customer D*15%
*Accounts Receivable was less than 10%
Schedules of Financial Instruments Fair value Hierarchy
The following table summarizes the Company’s financial instruments at fair value based on the fair value hierarchy for each class of instrument as of September 30, 2025:
Level 1Level 2Level 3Total
Convertible notes payable$— $— $13,351,000 $13,351,000 
Investment in equity securities— — 691,770 691,770 
Total$— $— $14,042,770 $14,042,770 
Schedule of Estimated Fair Value of Convertible Notes Payable Assumptions
The Company calculated the estimated fair value of the convertible notes payable during the nine months ended September 30, 2025 using the following assumptions:
Issuance date2/10/2025
Maturity date5/10/2026
Stock price
5.88 - 10.35
Expected volatility factor
124.8% - 137.2%
Risk-free interest rate
3.70% - 4.25%
Schedules of Changes in Convertible Notes Payable Measured at Fair Value
The following table presents changes in the Level 3 convertible notes payable measured at fair value for the nine months ended September 30, 2025:
Balance, January 1, 2025$— 
Additions14,432,879 
Fair value measurement adjustments12,939,387 
Redemption(1,650,000)
Conversion into common stock(12,371,266)
Balance, September 30, 2025$13,351,000 
Schedules of Revenue Disaggregated by Revenue Type
The following table presents the Company’s revenue disaggregated by revenue type:
Three months ended
September 30,
Nine months ended
September 30,
2025202420252024
Product related$8,471,548 $1,292,447 $12,191,488 $11,115,346 
Contract related1,174,844 — 2,303,143 3,210,799 
Total$9,646,392 $1,292,447 $14,494,631 $14,326,145 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Outstanding securities not included in the computation of diluted net loss per share because their effect would have been anti-dilutive include:
September 30,
2025
December
31, 2024
Series B Preferred Stock, as converted3,896 3,896 
Stock options4,787,364 5,242,308 
Warrants1,313,833 914,056 
Restricted stock2,030,408 1,544,027 
Total8,135,501 7,704,287